Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol

Study to characterise any drug-drug interaction between antimalarial Pyramax and CYP2D6 probe substrate metoprolol

• From: Department for International Development
• Published: 3 December 2014

• Document Type: Journal Article
• Theme: Health
• Authors: Duparc, S., Borghini-Fuhrer, I., Fleckenstein, L., Arbe-Barnes, S. and Miller, R.M.
  Show 4 more
  Morris, C.A., Lopez-Lazaro, L., Shin JangSik, and Pokorny, R.

Abstract

The objectives of this study were to characterize any drug-drug interaction between the antimalarial Pyramax (pyronaridine-artesunate [PA]) and the CYP2D6 probe substrate metoprolol and to assess the safety of 60-day or 90-day PA redosing, particularly with regard to liver biochemistry parameters.

Citation

Morris, C.A.; Pokorny, R.; Lopez-Lazaro, L.; Miller, R.M.; Arbe-Barnes, S.; Duparc, S.; Borghini-Fuhrer, I.; Shin JangSik; Fleckenstein, L. Pharmacokinetic Interaction between Pyronaridine-Artesunate and Metoprolol. Antimicrobial Agents and Chemotherapy 58 (10) 5900-5908. [DOI: 10.1128/AAC.02716-14]

Links

Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol

Published 3 December 2014